<DOC>
	<DOCNO>NCT02670343</DOCNO>
	<brief_summary>An open-label , single oral TU dose study conduct eight ( 8 ) hypogonadal men single study site . Each study participant receive single oral TU dose immediately prior standardize breakfast meal comprise 800 1000 calorie approximately 30 g fat . Blood sample collect 30 minute prior dose administration 0 pre-dose post dose follow hour post-dose ; 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 12 hour .</brief_summary>
	<brief_title>Phlebotomy Study Testosterone Undecanoate</brief_title>
	<detailed_description>This open-label , single oral dose , phlebotomy study design clarify issue influence blood collection tube T , DHT , TU DHTU measurement collect blood sample various collection tube small number hypogonadal men dose single oral TU dose form SEDDS formulation .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Male , 18 65 year age , inclusive , diagnosis hypogonadism screen total serum T &lt; 300 ng/dL . 2 . Adequate venous access allow blood sample collection via venous cannula . 3 . Naïve androgenreplacement therapy willing temporarily cease current T treatment willing remain form T except study medication throughout study . 4 . Voluntarily provide write informed consent participate study . Subjects meet follow exclusion criterion eligible : 1 . Significant intercurrent disease ( especially liver , kidney , heart disease , uncontrolled diabetes mellitus psychiatric illness ) 2 . Abnormal prostate digital rectal examination , elevate PSA ( PSA &gt; 4 ng/mL ) , AUA Symptom Score ≥ 15 point and/or history prostate CA . 3 . BMI le 18 kg/m2 great 37 kg/m2 4 . Serum transaminases &gt; 2 time upper limit normal ( ULN ) serum bilirubin &gt; 2.0 mg/dL . 5 . History severe multiple allergy , severe adverse drug reaction . A known hypersensitivity lidocaine surgical dressing may use study procedure . 6 . History abnormal bleeding tendency thrombophlebitis unrelated venipuncture intravenous cannulation . 7 . Oral , topical buccal T therapy within previous one week , intramuscular T injection within previous 4 week . 8 . Parenteral Tundecanoate therapy within past 6 month . 9 . Use dietary supplement may increase serum T , within previous 4 week . 10 . Known malabsorption syndrome and/or current treatment oral lipase inhibitor , bile acidbinding resin , colestipol , fibric acid derivative , clofibrate , gemfibrozil , probucol . 11 . Smokers unable refrain smoking required confinement period . 12 . History , current evidence , abuse alcohol drug substance . 13 . Receipt research study drug within 30 day study . 14 . Blood donation within 12 week period initial study dose . 15 . Hematocrit le 35 % great 50 % . 16 . History clinically significant polycythemia follow treatment testosterone replacement product . 17 . Current use paroxetine , clomipramine , antiandrogens , estrogen , potent P450 enzyme inducer , barbiturate . 18 . History uncontrolled sleep apnea .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>